This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients

This study has been completed.
Information provided by (Responsible Party):
Mahmut Ilker Yilmaz, Gulhane School of Medicine Identifier:
First received: October 4, 2012
Last updated: October 6, 2012
Last verified: October 2012
There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria. The aim of this study was to find out whether the beneficial effects of RAS blockage in diabetic proteinuria has any relation with the alteration of ADMA and FGF-23 levels. We searched for the effects of ACE inhibitor ramipril on the clinical and laboratory parameters of diabetic patients with proteinuria.

Condition Intervention Phase
Proteinuria Diabetic Nephropathy Chronic Kidney Disease Drug: Ramipril Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Mahmut Ilker Yilmaz, Gulhane School of Medicine:

Primary Outcome Measures:
  • Flow Mediated Dilatation

Secondary Outcome Measures:
  • FGF-23

Enrollment: 78
Study Start Date: January 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramipril Drug: Ramipril
ramipril 10 mg/day during 3 months

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • CKD stage 1 patients
  • Older than 18 years of age
  • Type 2 Diabetic patients
  • Proteinuria

Exclusion Criteria:

  • History of coronary artery disease
  • Smokers
  • Taking statins or renin-angiotensin blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01703234

Gulhane School of Medicine
Ankara, Turkey
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

Responsible Party: Mahmut Ilker Yilmaz, Assoc.Prof., Gulhane School of Medicine Identifier: NCT01703234     History of Changes
Other Study ID Numbers: GATARAMFGF232012
Study First Received: October 4, 2012
Last Updated: October 6, 2012

Keywords provided by Mahmut Ilker Yilmaz, Gulhane School of Medicine:
FGF-23 , ramipril, endothelial dysfunction

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Diabetic Nephropathies
Urologic Diseases
Renal Insufficiency
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on August 21, 2017